Arcturus Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Arcturus Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 2 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Arcturus Therapeutics: 6 sponsored US clinical trials, 2 recruiting.

Arcturus Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is OTCD, with 1 trials.

Upper-quartile sponsor footprint

Arcturus Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 2

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

NCT06747858
RECRUITING Phase 2

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

NCT06488313
COMPLETED Phase 1

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

NCT06602531
COMPLETED Phase 1

A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

NCT05037097
TERMINATED Phase 2

A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

NCT04668339
COMPLETED Phase 1

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

NCT04442347

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3

Therapeutic Areas

OTCD 1
OTC Deficiency 1
CFTR Gene Mutation 1
Ornithine Transcarbamylase Deficiency 1
Cystic Fibrosis 1

What is open in the Arcturus Therapeutics pipeline

2 recruiting of 6 indexed (33% open); 3 completed (50%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: OTCD (1 trial), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Arcturus Therapeutics: open-pipeline peers nationwide

Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Arcturus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%20%40%60%80% Total trials Recruiting share Arcturus Therapeutics23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Arcturus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Arcturus Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Arcturus Therapeutics page

6 registered trials is a research-attention snapshot, not an endorsement of Arcturus Therapeutics or any single study.

  • 2 of Arcturus Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • OTCD is the condition Arcturus Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See OTCD trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Arcturus Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.